Take the ‘Tamiflu’ Approach

Overlooked during the global fixation on vaccinations: oral antivirals pills.
 
A pill-based “Tamiflu approach” would be easier than current therapies like monoclonal antibodies and convalescent plasma that need intravenous infusions.
 
Tantalizing Advantage: An antiviral could block SARS-CoV-2’s replication and ”provide broad spectrum coverage against emerging SARS-CoV-2 variants,” a MedPage Today article notes. 

In the works now: 

  • Molnupiravir, which knocked out measurable virus in 5 days in a 175-person phase II trial
  • Upamostat in a phase II/III trial
  • AT-527 for “mild to moderate COVID-19 in the outpatient setting” in phase II.

Another to watch: favipiravir in a phase II trial.

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top